Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Completed · Phase 2
Conditions studied: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
In brief
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Key facts
- Study ID
- NCT02864381
- Run by
- Gilead Sciences
- People needed
- 144
- Starts
- 2016-09-01
- Expected to finish
- 2019-08-23
- Last updated by the study team
- 2020-09-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Los Angeles, California, United States
- Study site — San Francisco, California, United States
- Study site — Chicago, Illinois, United States
- Study site — Fort Wayne, Indiana, United States
- Study site — St Louis, Missouri, United States
- Study site — New York, New York, United States
- Study site — Albury, New South Wales, Australia
- Study site — Wahroonga, New South Wales, Australia
- Study site — Douglas, Queensland, Australia
- Study site — Hobart, Tasmania, Australia
- Study site — La Louvière, Hainaut, Belgium
- Study site — Ghent, Oost-Vlaanderen, Belgium
- Study site — Leuven, Vlaams Brabant, Belgium
- Study site — Brest, Finistère, France
- Study site — Reims, Marne, France
- Study site — Villejuif, Val-de-Marne, France
- Study site — Budapest, Hungary
- Study site — Debrecen, Hungary
- Study site — Meldola, Forli-Cesena, Italy
- Study site — Genova, Ligura, Italy
- Study site — Milan, Lombardy, Italy
- Study site — Pisa, Tuscany, Italy
- Study site — Brzozów, Podkarpackie Voivodeship, Poland
- Study site — Poznan, Poland
- Study site — Warsaw, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.